Claudio Faria

Indirect costs associated with metastatic breast cancer

Abstract Objective: To compare the indirect costs of productivity loss between metastatic breast cancer (MBC) and early stage breast cancer (EBC) patients, as well as their respective family members. Methods: The MarketScan® Health and Productivity Management database (2005–2009) was used. Adult BC patients eligible for employee benefits of sick leave and/or short-term disability were identified with ICD-9 codes. Difference in sick leave and short-term disability days was calculated between MBC patients and their propensity score matched EBC cohort and general population (controls) during a 12-month follow-up period. Generalized linear models were used to examine the impact of MBC on indirect costs to patients and their families. Results: A total of 139 MBC, 432 EBC, and 820 controls were eligible for sick leave and 432 MBC, 1552 EBC, and 4682 controls were eligible for short-term disability (not mutually exclusive). After matching, no statistical difference was found in sick leave days and the associated costs between MBC and EBC cohorts. However, MBC patients had significantly higher short-term disability costs than EBC patients and controls (MBC:

Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting

6166 ± 

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting

9194 vs EBC:

Comparative effectiveness and resource utilization of nab -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

3690 ± 

Real-world analysis of eribulin in metastatic breast cancer (MBC): An assessment of time to treatment failure (TTF) in a community oncology setting.

6673 vs Controls:

Comparative effectiveness of early-line nab-paclitaxel (nab-P) versus eribulin in patients (pts) with metastatic breast cancer (MBC): A U.S. real-world analysis.

558 ± 

Understanding the impact of settings of care and the development of chemotherapy-induced nausea and vomiting within a population of commercially insured patients.

2487, both p < 0.001). MBC patients had more sick leave cost than controls (

Investigating rates of CINV across settings of care in Medicare: A retrospective claims-based analysis.

2383 ± 

Eribulin treatment patterns in patients with and without prior anthracycline use.

5539 vs

A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer patients.

1282 ±